Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal dominant tumor predisposition disorder caused by pathogenic variants in the MAX gene, characterized by an increased risk of pheochromocytoma and paraganglioma.
No clinical trials have been registered for MAX-related tumor predisposition.
6 publications have been identified in PubMed for MAX-related tumor predisposition. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (33%), and Epidemiology / Natural History (17%).
Salle L (2026). [PMID: 41521775](https://pubmed.ncbi.nlm.nih.gov/41521775/). *Eur J Endocrinol*. [Case Report / Case Series]
Saito E (2025). [PMID: 40268426](https://pubmed.ncbi.nlm.nih.gov/40268426/). *J Vet Med Sci*. [Case Report / Case Series]
Rednam SP (2025). [PMID: 40549645](https://pubmed.ncbi.nlm.nih.gov/40549645/). *Clin Cancer Res*. [Review / Meta-Analysis]
Żurawska J (2025). [PMID: 39863726](https://pubmed.ncbi.nlm.nih.gov/39863726/). *Sci Rep*. [Epidemiology / Natural History]
Eren A (2025). [PMID: 40492017](https://pubmed.ncbi.nlm.nih.gov/40492017/). *JCEM Case Rep*. [Case Report / Case Series]
Data assembled from 2 of 12 sources · Last updated Sep 18, 2026, 8:53 PM UTC
Common questions about MAX-related tumor predisposition